Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463408 | 1.00 | EPHX1 (0.52) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL7980872 | 1.00 | EPHX1 (0.52) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL121264 | 1.00 | EPHX1 (0.52) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL235213 | 0.97 | — | — | |
| Iodomethane SCHEMBL27553883 | 0.93 | EPHX1 (0.48) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL966449 | 0.92 | — | — | |
| SCHEMBL871360 | 0.85 | — | — | |
| SCHEMBL9270019 | 0.81 | EPHX1 (0.50) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL9273496 | 0.81 | EPHX1 (0.50) | EPHX1CA12CA1CA2CA9 | |
| Bicarbonate SCHEMBL11518297 | 0.81 | EPHX1 (0.56) | EPHX1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-111032668-B | Optically active 2,3-bisphosphinylpyrazine derivative, process for producing the same, transition metal complex, and process for producing organoboron compound | 日本化学工业株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11084835-B2 | 2,3-bisphosphinopyrazine derivative, method for producing same, transition metal complex, asymmetric catalyst, and method for producing organic boron compound | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-11053265-B2 | Optically active substituted 2,3-bisphosphinoquinoxalines and processes for producing the same | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20210047351-A1 | 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-02-18 | — | — | US | disclosed |
| US-20200377536-A1 | OPTICALLY ACTIVE 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2020-12-03 | — | — | US | disclosed |
| CN-111655708-A | 2, 3-bisphosphinylpyrazine derivative, process for producing the same, transition metal complex, chiral catalyst, and process for producing organoboron compound | 日本化学工业株式会社 | 2020-09-11 | — | — | CN | disclosed |
| WO-2009001968-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-12-31 | — | — | WO | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-6174877-B1 | EXCELLANT BACTERICIDES, ORAL ABSORBABILITY AND STABILITY; IMPROVE THE STABILITY TO RENAL DEHYDROPEPTIDASE I (DHP-I); 2-(2-(N-HETEROCYCLIC-ETHYLTHIO-) DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-5948774-A | EXCELLENT ANTIBACTERIAL ACTIVITIES ON A BROAD RANGE OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA, ESPECIALLY STAPHYLOCOCCUS AUREUS AND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0876370-A1 | CARBAPENEM COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-11-11 | — | — | EP | disclosed |
| EP-0828744-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-03-18 | — | — | EP | disclosed |
| WO-1997025325-A1 | CARBAPENEM COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-17 | — | — | WO | disclosed |
| WO-1996038451-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-05 | — | — | WO | disclosed |
| WO-1993011669-A1 | USE OF 3-PHENYLURACIL DERIVATIVES FOR THE DESICCATION AND ABSCISSION OF PLANT PARTS | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377536-A1 | OPTICALLY ACTIVE 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | ORC3, BMP2, TERT | EPHX1 4721/4885CA12 836/4885CA1 1740/4885 |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | EPHX1 3046/4885CA12 1710/4885CA1 1800/4885 |
| US-20210047351-A1 | 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | BPGM, COASY, BRSK2 | EPHX1 4781/4885CA12 499/4885CA1 1564/4885 |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | EPHX1 3046/4885CA12 1710/4885CA1 1800/4885 |
| US-11084835-B2 | 2,3-bisphosphinopyrazine derivative, method for producing same, transition metal complex, asymmetric catalyst, and method for producing organic boron compound | BPGM, BRSK2, COASY | EPHX1 4773/4885CA12 519/4885CA1 1566/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | EPHX1 2170/4885CA12 2116/4885CA1 1635/4885 |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | EPHX1 3046/4885CA12 1710/4885CA1 1800/4885 |
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | EPHX1 3046/4885CA12 1710/4885CA1 1800/4885 |
| US-11053265-B2 | Optically active substituted 2,3-bisphosphinoquinoxalines and processes for producing the same | TBXA2R, TBC1D15, P2RY2 | EPHX1 4143/4885CA12 2818/4885CA1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.